Analyst Activity – Beaufort Securities Reiterates Buy on Hutchison China MediTech Limited (LON:HCM)

Analyst Ratings For Hutchison China MediTech Limited (LON:HCM)

Story continues below

Today, Beaufort Securities reiterated its Buy rating on Hutchison China MediTech Limited (LON:HCM).

There are 3 buy ratings on the stock.

The current consensus rating on Hutchison China MediTech Limited (LON:HCM) is Buy (Score: 3.00) with a consensus target price of GBX 2,630 per share, a potential .

Some recent analyst ratings include

  • 3/6/2017-Beaufort Securities Reiterated Rating of Buy.
  • 2/20/2017-Panmure Gordon Reiterated Rating of Buy.
  • 4/11/2016-Stifel Nicolaus initiated coverage with a Buy rating.


    About Hutchison China MediTech Limited (LON:HCM)
    Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures markets and distributes prescription drugs and consumer health products in China.

    Recent Trading Activity for Hutchison China MediTech Limited (LON:HCM)
    Shares of Hutchison China MediTech Limited closed the previous trading session at 2,316.50 up +34.00 1.49% with 0 shares trading hands.

    An ad to help with our costs